<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DEFEROXAMINE MESYLATE</span><br/>(de-fer-ox'a-meen)<br/><span class="topboxtradename">Desferal<br/></span><b>Classifications:</b> <span class="classification">chelating agent</span>; <span class="classification">antidote</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>Chelating agent isolated from <i>Streptomyces pilosus</i> with specific affinity for ferric ion and low affinity for calcium.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Binds ferric ions to form a stable water-soluble chelate readily excreted by kidneys. Main effect is removal of iron from
         ferritin, hemosiderin, and transferrin.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct in treatment of acute iron intoxication. Has been used in management of hemochromatosis and hemosiderosis secondary
         to increased iron storage as from multiple transfusions used in treatment of congenital anemias, e.g., thalassemia (Cooley's
         or Mediterranean anemia), sickle cell anemia, and other chronic anemias.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To promote aluminum excretion in aluminum-associated dialysis encephalopathy and aluminum accumulation in bones of patients
         in renal failure.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe renal disease, anuria, pyelonephritis; pregnancy (category C), and children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of pyelonephritis; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Iron Intoxication</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span> 1 g followed by 500 mg at 4 h intervals for 2 doses, subsequent doses of 500 mg q412h may be given if necessary (max:
               6 g/24 h), infuse at <img src="../images/special/lesserorequal.gif"/>15 mg/kg/h<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> 20 mg/kg followed by 10 mg/kg at 4 h intervals for 2 doses, subsequent doses of 10 mg/kg q412h may be given if necessary
               (max: 6 g/24 h), infuse at <img src="../images/special/lesserorequal.gif"/>15 mg/kg/h<br/><br/><span class="indicationtitle">Chronic Iron Overload</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IM</span> 500 mg1 g/d <span class="rdroute">IV</span> 2 g with each unit of blood transfused, infuse at <img src="../images/special/lesserorequal.gif"/>15 mg/kg/h <span class="rdroute">SC</span> 12 g/d (2040 mg/kg/d) infused over 824 h (<i>Child</i>, max: 6 g/d or 2 g/dose)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute by adding 2 mL sterile water for injection to 500-mg vial to yield 250 mg/mL. Dissolve drug completely before
            it is withdrawn from vial.
         </li>
<li>Administer SC dose over 824 h using portable minipump devices.</li>
<li>Use IM route for all patients not in shock; preferred route for acute intoxication.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>For infants and children: Verify correct IV concentration and rate with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span>   Reconstitute by adding 5 mL sterile water for injection to 500-mg vial to yield 100 mg/mL. After drug is completely dissolved, withdraw prescribed amount from vial and add to NS, D5W, or RL solution. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span>  Give initial 1000 mg dose at a rate not to exceed 15 mg/kg/h.  Give subsequent 500 mg doses at a rate of 125 mg/h. Do not infuse IV rapidly; such infusion is associated with the occurrence of more adverse effects. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at room temperature 15°30° C (59°86° F) for not longer than 1 wk. Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (generalized itching, cutaneous wheal formation, rash, fever, <span class="speceff-life">anaphylactoid reaction</span>). <span class="typehead"> CV:</span> Hypotension, tachycardia. <span class="typehead"> Special Senses:</span>  Decreased hearing; blurred vision, decreased visual acuity and visual fields, color vision abnormalities, night blindness,
      retinal pigmentary degeneration. <span class="typehead">GI:</span> Abdominal discomfort, diarrhea. <span class="typehead">Urogenital:</span> Dysuria, exacerbation of pyelonephritis, orange-rose discoloration of urine. <span class="typehead">Other:</span> <span class="speceff-common">Pain and induration at injection site</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Widely distributed in body tissues. <span class="typehead">Metabolism:</span> Forms nontoxic complex with iron. <span class="typehead">Elimination:</span> Excreted primarily in urine; some excreted in feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform baseline kidney function tests prior to drug administration.</li>
<li>Monitor injection site. If pain and induration occur, move infusion to another site.</li>
<li>Monitor I&amp;O ratio and pattern. Report any change. Observe stools for blood (iron intoxication frequently causes necrosis of
            GI tract).
         </li>
<li> 								Note: Periodic ophthalmoscopic (slit lamp) examinations and audiometry are advised for patients on prolonged or high-dose therapy
            for chronic iron overload. 							
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Deferoxamine chelate makes urine turn a reddish color.</li>
<li>Report blurred vision or any other visual abnormality.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>